Locally recurrent prostate cancer with RB1/TP53 alterations successfully treated by salvage focal brachytherapy: a case report.

IF 1.5 Q3 UROLOGY & NEPHROLOGY
Takahiro Komori, Takeo Kosaka, Tomoki Tanaka, Keitaro Watanabe, Yota Yasumizu, Shuji Mikami, Mototsugu Oya
{"title":"Locally recurrent prostate cancer with RB1/TP53 alterations successfully treated by salvage focal brachytherapy: a case report.","authors":"Takahiro Komori,&nbsp;Takeo Kosaka,&nbsp;Tomoki Tanaka,&nbsp;Keitaro Watanabe,&nbsp;Yota Yasumizu,&nbsp;Shuji Mikami,&nbsp;Mototsugu Oya","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Retinoblastoma transcriptional corepressor 1 (RB1) and tumor protein p53 (TP53) are well-known tumor suppressor genes; their alterations are associated with poor prognosis in human malignancies and quite rare in locally recurrent cases. The patient was a 58-year-old man who was diagnosed with cT1cN0M0 prostate cancer with Gleason score of 3+3=6 and underwent brachytherapy as the initial treatment. Local recurrence was detected in the left lobe of the prostate 154 months later and whole-exome sequencing that was performed at the request of the patient revealed RB1 loss-of-heterozygosity and TP53 p.I162Rfs*27 mutations. He underwent salvage focal brachytherapy with <sup>125</sup>I seeds and serum prostate-specific antigen levels has been stabilized without any genitourinary or gastrointestinal toxicity.</p>","PeriodicalId":7438,"journal":{"name":"American journal of clinical and experimental urology","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461036/pdf/ajceu0011-0339.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of clinical and experimental urology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Retinoblastoma transcriptional corepressor 1 (RB1) and tumor protein p53 (TP53) are well-known tumor suppressor genes; their alterations are associated with poor prognosis in human malignancies and quite rare in locally recurrent cases. The patient was a 58-year-old man who was diagnosed with cT1cN0M0 prostate cancer with Gleason score of 3+3=6 and underwent brachytherapy as the initial treatment. Local recurrence was detected in the left lobe of the prostate 154 months later and whole-exome sequencing that was performed at the request of the patient revealed RB1 loss-of-heterozygosity and TP53 p.I162Rfs*27 mutations. He underwent salvage focal brachytherapy with 125I seeds and serum prostate-specific antigen levels has been stabilized without any genitourinary or gastrointestinal toxicity.

挽救性局灶近距离治疗局部复发性前列腺癌伴RB1/TP53改变1例。
视网膜母细胞瘤转录辅抑制因子1 (RB1)和肿瘤蛋白p53 (TP53)是众所周知的肿瘤抑制基因;它们的改变与人类恶性肿瘤的不良预后有关,在局部复发病例中相当罕见。患者男,58岁,确诊为cT1cN0M0前列腺癌,Gleason评分3+3=6,初始治疗为近距离放疗。154个月后在前列腺左叶检测到局部复发,应患者要求进行全外显子组测序,发现RB1杂合性缺失和TP53 p.I162Rfs*27突变。他接受了125I粒子补救性局灶近距离放射治疗,血清前列腺特异性抗原水平稳定,无泌尿生殖系统或胃肠道毒性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
8.30%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信